Company intelligence / Profile preview
Esanex, Inc.
Indianapolis, Indiana, United Statesesanexpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Esanex, Inc. developed highly selective oral Hsp90 inhibitors for oncology indications. Its lead asset SNX‑5422 advanced through multiple Phase 1 studies in solid tumors and hematologic malignancies such as CLL. The most recent known trial combined SNX‑5422 with the BTK inhibitor ibrutinib to address residual disease in CLL patients but was terminated. Earlier studies explored combinations with standard chemotherapies in lung cancer. There are no reported late-stage or commercial programs.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborated with academic centers such as The Ohio State University for clinical trials[6]. No major pharma partnerships disclosed.
Beyond the preview
Go deeper on Esanex, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Esanex, Inc..